The on-body injector's fixed, flat-rate dosage simplifies clinical workflow and improves safety by eliminating the need for constant, error-prone dose recalculations based on patient weight changes, which is standard for many body surface area (BSA)-based cancer therapies.

While fee-for-service models incentivize in-clinic treatments, value-based care shifts the focus to outcomes and overall cost. Under these new models, home dialysis—which offers better patient outcomes and lower societal costs—becomes more profitable for providers, creating a powerful financial incentive to drive adoption.

Unlike imaging that requires specialized centers, blood tests can be administered anywhere with basic phlebotomy services. This eliminates geographic and logistical barriers, making advanced diagnostics accessible to rural and underserved populations and reframing access as a human right.

The rapid and successful rollout of complex bispecific therapies into community settings is primarily driven by enhanced nursing staff skills and protocols for risk stratification. This combination allows for safe outpatient administration, preventing hospital admissions and broadening patient access beyond large academic centers.

The friction of navigating insurance and pharmacies is so high that chronic disease patients often give up, skipping tests or medications and directly worsening their health. AI can automate these tedious tasks, removing the barriers that lead to non-compliance and poor health outcomes.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Subcutaneous on-body device delivery of anti-CD38 antibodies like isatuximab nearly eliminates the high risk of infusion-related reactions common with intravenous administration, especially during the first dose. This significantly enhances patient safety and comfort in the clinic.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

A major challenge in managing high cholesterol is patient adherence to daily medication for life. New therapies like Inclisiran use mRNA silencing and require only two injections per year, dramatically improving adherence for busy or non-compliant individuals.